Apatinib Clinical Trials

A listing of Apatinib medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy.

kidney function tests
apatinib
cancer of the head
advanced head and neck squamous cell carcinoma
locally advanced head and neck squamous cell carcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

The participants will receive neoadjuvant PD-1 inhibitor (camrelizumab) combined with antiangiogenic drug (apatinib) or platinum-based chemotherapy.

proto-oncogene tyrosine-protein kinase ros
metastasis
blood transfusion
pd-1 inhibitor
anticoagulants
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

The secondary objective of the study was to assess the safety of Apatinib or/and Repaglinide and Bupropion.

solid tumor
apatinib
targeted therapy
blood transfusion
colony stimulating factor
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma

This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

blood component
pd-1 inhibitor
neutrophil count
hepatitis
cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

The innovation of this study is the combination of immune checkpoint inhibitor, Camrelizumab, and targeted drug against VEGFR, Apatinib, as an inductive therapy to treat the patients with locally advanced OSCC, followed with radical surgery and post-operative radiotherapy/chemoradiotherapy, the major pathologic response and safety will be evaluated as the primary …

immune checkpoint inhibitor
metastasis
chemoradiotherapy
squamous cell carcinoma of the head and neck
neovascularization
  • 0 views
  • 05 Aug, 2020
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study …

tyrosine
apatinib
metastasis
postoperative complication
growth factor
  • 0 views
  • 16 Feb, 2024
  • 1 location